The International Journal of Mycobacteriology

: 2021  |  Volume : 10  |  Issue : 3  |  Page : 285--292

The effect of collaborative care on treatment outcomes of newly diagnosed tuberculosis patients with Type-2 diabetes mellitus and adverse drug reaction presentations: A prospective study

Foluke Adenike Ayeni, Olubukola O Oyetunde, Bolajoko A Aina 
 Department of Clinical Pharmacy and Biopharmacy, Faculty of Pharmacy, University of Lagos, Lagos, Nigeria

Correspondence Address:
Foluke Adenike Ayeni
Department of Clinical Pharmacy and Biopharmacy, Faculty of Pharmacy, University of Lagos, Lagos


Background: The burdens of tuberculosis (TB) and diabetes mellitus (DM) in Nigeria are high. DM often goes unrecognized in TB patients, resulting in poorer treatment outcomes compared with TB patients only. This study set out to compare TB treatment outcomes and associated factors in TB only and TBDM patients when a collaborative care (CC) model is in place. Methods: A prospective quasi-experimental study, modeled after the World Health Organization and The Union's Collaborative Framework for Care and Control of TB and DM was carried out among TB patients in two chest clinics in Lagos state. Patients were grouped into TB only, who received the usual TB care, directly observed treatment, short course (DOTS), and TBDM, who received DOTS and CC. Data were analyzed with IBM Statistical Package for the Social Sciences, version 23.0. Chi-square and multivariate analysis determined the association between treatment success and CC. Statistical tests were calculated at 95% confidence intervals and considered significant when P value is < 0.05. Results: Of 671 participants in the study, 52 (7.7%) had DM. At TB treatment completion, there was no statistically significant difference in outcomes between TBDM and TB-only patients (P = 0.40). Patients who received CC were about 32 (OR: 31.60, 95% CI: 3.38-293), and 5 times (OR: 5.08, 95% CI: 1.35-19.17) more likely to achieve success and cure, respectively, compared to those who did not. Conclusion: Provision of CC with DOTS ensured improved TB treatment outcomes in TBDM patients. Recommendations of WHO/The Union are feasible in our setting.

How to cite this article:
Ayeni FA, Oyetunde OO, Aina BA. The effect of collaborative care on treatment outcomes of newly diagnosed tuberculosis patients with Type-2 diabetes mellitus and adverse drug reaction presentations: A prospective study.Int J Mycobacteriol 2021;10:285-292

How to cite this URL:
Ayeni FA, Oyetunde OO, Aina BA. The effect of collaborative care on treatment outcomes of newly diagnosed tuberculosis patients with Type-2 diabetes mellitus and adverse drug reaction presentations: A prospective study. Int J Mycobacteriol [serial online] 2021 [cited 2022 Jan 21 ];10:285-292
Available from:

Full Text


Tuberculosis (TB) and Diabetes Mellitus (DM) are recognized major health problems of epidemic proportions.[1] TB is a global leading cause of death infecting about 10 million people annually,[2] and concurrently, about 642 million people are expected to be living with DM by the year 2040, up from 415 million in 2015.[3] There are concerns that TB control is being undermined by the increasing number of people living with TB and DM, which currently stands at an estimated 8.0% in the African region.[4] Poor glycemic control and/or uncontrolled DM in diabetic patients increases the risk of developing active TB infection. It also adversely affects TB disease progression, and co-occurrence of both diseases results in mutual negative interactions leading to worsening prognosis and treatment outcomes.[5],[6]

According to the World Health Organization (WHO), Nigeria has the highest burden of TB, and the third-highest burden of DM, in Africa.[1],[7] Several studies, carried out in different settings within the country revealed that the prevalence of DM in TB patients is substantial, ranging from 9.4% to 12.3%.[8],[9] Despite this, the presence of DM in TB patients undergoing TB treatment often go unrecognized, as it is not part of routine care. Thus, DM is often missed in TB patients, DM care is not given, and TB patients with comorbid DM (TBDM patients) often have poorer TB treatment outcomes compared to their TB-only counterparts.[10]

In response to the TBDM management challenges, the World Health Organization (WHO) and the International Union Against TB and Lung Disease (The Union) launched a Collaborative Framework for Care and Control of TB and DM.[11] This framework seeks to guide the development and implementation of collaborative activities aimed at decreasing the joint burden of DM and TB in populations affected by both diseases. This study adopted the framework to develop essential collaborative activities for the management of TBDM comorbidity in two chest clinics in Lagos state, Nigeria. The study thus aimed at determining the effect of collaborative care (CC) on TB treatment outcomes of TB only and TBDM patients and associated factors of treatment success when managed under a CC model.


Study design and setting

A prospective, observational study which employed a quasi-experimental study design was conducted among a cohort of TB patients registered in two (a secondary and a specialist) chest clinics in Lagos state, Nigeria. Lagos State, located in the south west part of Nigeria, and home to about 21 million people was created in 1967 and is the commercial nerve center of the country.[12]

Newly diagnosed TB patients with previously undiagnosed DM, aged 18 years and above and known Type 2 DM patients recently diagnosed for TB were included in the study, while TB patients <18 years of age, known or suspected MDR-TB cases, and patients diagnosed with any disease condition other than TB and DM were excluded to avoid the confounding effect on treatment outcome. The sample size for Cross-Sectional, Cohort, and Randomized Clinical Trials at 95% confidence interval (CI) was used to calculate the sample size.[13] Based on required parameters, a sample size of 619 for TB only and 52 for TBDM patients was calculated.

Study instrument/study procedure

A total of 671 patients were recruited using a non-probability consecutive sampling technique.

A structured, pre-tested questionnaire comprising 3 sections was developed to collect data.

Section A obtained information on the patient's sociodemographic data. Section B recorded clinical data such as type and category of TB disease, contact with a past or current TB case, symptoms, habitual risk factors for both TB and DM, family history of TB and DM, and complications of the disease if any. Also recorded for patients with pre-existing DM was the type of DM disease, duration of disease, prescribed antidiabetic medications, and adherence to treatment. Section C recorded reported adverse reactions experienced after treatment initiation, and TB treatment outcomes at the end of Directly Observed Treatment, Short-course (DOTS) therapy.

Diagnosis of TB was based on existing practices in the study center, according to the national TB and Leprosy Control Program and WHO guidelines.[14] Screening and diagnosis of DM were assessed with an initial measurement of random blood glucose (RBG) at treatment initiation, followed with fasting blood glucose (FBG) and glycated hemoglobin (HbA1c) levels measurement one week after, if RBG levels are above 200 mg/dL.[15] Body weights of all recruited patients before starting, and at the end of TB treatment were recorded. Two blood pressure measurements were taken while the patient was in a sitting position and the average of the two readings recorded. Based on their DM status, study participants were divided into two groups: Patients with TB and no DM as TB only patients, and patients with both TB and newly diagnosed or existing DM as TBDM patients [Figure 1].{Figure 1}

Both groups of patients were managed under DOTS therapy (2RHZE/4RH) for six months[14] while TBDM patients, in addition, were managed under CC which comprised of DOTS, pharmacist's intervention which in turn comprised of adverse drug reaction monitoring, drug-related problem resolution, HbA1c, and monthly FBG monitoring, drug and disease education, and DM management in an endocrinology clinic in accordance with International diagnostic criteria.[15] TB-only patients were passively followed up, while TBDM patients were actively followed with monthly evaluations till the end of TB treatment.

Classifications of treatment outcomes

TB Treatment outcomes were classified and defined in accordance with WHO recommendations.[16] as shown in [Table 1].{Table 1}

DM treatment outcomes were set as the reduction in symptoms, FBG and HbA1c levels,[17] and successful TB treatment outcomes.

Ethical approval

Ethical approval was obtained from the Health Research and Ethics Committee of Lagos University Teaching Hospital (Assigned No: ADM/DCST/HREC/APP/665). Administrative approval was obtained from Lagos State Health Service Commission (Ref No: SHMB/728/Vol VI/) and informed consent was obtained from all recruited patients.

Data analysis

Data were analyzed using IBM Statistical Package for the Social Sciences (SPSS), version 23.0 (SPSS Inc, Chicago, IL, USA). Summary statistics were presented in tables and charts as frequencies and proportions. Sociodemographic and clinical data were compared between TB only and TBDM patient groups. Differences in proportions between groups were compared by Chi-square analysis. The occurrence of Adverse drug reactions (ADRs) was presented in frequencies and percentages. The association between treatment success and CC, sociodemographic and clinical characteristics of the study participants and presence of ADRs was assessed through univariate, bivariate, and multivariate analyses. Only variables that were significant to a P = 0.05 were included in the multivariate model. All statistical tests were two-tailed, calculated at 95% CIs and considered significant at a P < 0.05.


Patient characteristics

This study revealed a prevalence of DM of 52 (7.7%) among 671 responding TB patients. Compared with TB only patients, TBDM patients were older 48 (92.3%), more female 28 (53.8%) than males, less commonly smear positive 30 (51.7%), and presented with higher blood pressures 24 (46.2%) and body mass index 13 (25%). They also had higher mean random (318.8 ± 90.6) and fasting (207.4 ± 80.3) blood glucose values. Patients in both groups presented with similar pulmonary cases [Table 2]. The presence of DM was significantly associated with gender and family history of DM (P = 0.01), age, weight, functionality status and coughing with sputum (P = 0.00), and contact with active TB case (P = 0.02).{Table 2}

About half, 24 (46.2%) of TBDM patients were newly diagnosed with DM [Table 3]. Compared with known TBDM patients, newly diagnosed TBDM patients were younger (48.5 ± 10.7 years), more female, 15 (62.5%), presented with higher RBG (331.6 ± 98.9) and FBG (216. 8 ± 100.7) values but lesser HbA1c (10.3 ± 2.7) and hypertensive cases, 6 (25%).{Table 3}

Mean body weights were comparable in both patient groups. Mean HbA1c for all TBDM patients reduced from 10.8% at treatment initiation to 9.7% at treatment completion. Similarly, the mean HbA1c for TBDM patients who were in the CC group reduced from 10.5% at treatment initiation to 8.8% at treatment completion. Average monthly FBG for all TBDM patients reduced from 206.8 mg/dL at TB treatment initiation to 152.1 mg/dL at treatment completion.

Treatment outcomes and associated factors

Equal proportions of patients in both groups (53.8%) achieved cure. TBDM patients recorded more treatment completion, 16 (30.8%) and deaths, 4 (7.7%) compared to TB patients only. More TB-only patients, 68 (11%) and 17 (2.7%) were lost to follow-up and transferred out of their treatment centers, respectively. There was no statistically significant difference in overall treatment success (P = 0.40) and other outcomes between both patient groups when CC was in place [Table 4].{Table 4}

Univariate analysis evaluating the impact of CC among TBDM patients on treatment outcomes revealed a significant association with treatment success (P = 0.001) and cure rates (P = 0.01). Patients who received CC were about 32 (odds ratio [OR]: 31.60, 95% CI: 3.38–293), and 5 times (OR: 5.08, 95% CI: 1.35–19.17) more likely to achieve success and cure respectively compared to those who did not [Table 4]. No patient in CC was lost to follow-up, transferred out or died.

Bivariate analysis revealed adherence to treatment (P = 0.001), presence of ADRs (P = 0.008), and CC status (P = 0.001) were significantly associated with treatment success [Table 5].{Table 5}

When subjected to multivariate analysis, patients who adhered to treatment and were in CC were six times (OR: 6.37, 95% CI: 2.46–17.29, P = 0.015), and four times (OR: 3.97, 95% CI: 1.82–9.65, P = 0.028) more likely to experience treatment success, respectively [Table 6].{Table 6}

Adverse drug reaction incidence

Overall, a total of 439 ADRs were reported in this study. Almost half of participants, 280 (41.7%), reported at least one ADR. More TBDM patients, 42 (80.8%), than TB only patients 238 (38.4%) significantly reported an ADR (P = 0.000) [Table 7]. Reports of 2 or more ADRs by a patient were statistically significantly higher (P = 0.0001) among TBDM patients, who, based on Hartwig's severity scale also reported significantly more moderately severe ADRs, 14 (33.3%; P = 0.003), which required more therapy modifications, 12 (28.6%; P = 0.002) compared to TB only patients. They also reported higher percentages of ADRs in all organ systems than TB-only subjects [Figure 2]. Commonly reported ADRs associated with DM were GIT (61.5%), systemic (40.4%), and skin related (17.3%) ADRs.{Figure 2}{Table 7}


Despite the reported substantial prevalence of DM among TB patients in Nigeria, there is limited data available regarding the management of comorbidity. This study revealed a 7.7% prevalence of DM among recruited TB patients, consistent with national values and an estimated African prevalence (8.0%)[4],[8],[9]

The study demonstrated that there was no significant difference in TB treatment outcomes between TB only and TBDM patients when they were managed collaboratively. TBDM patients were 32 times, and five times more likely to achieve treatment success and cure respectively under CC than with traditional management in separate clinics, a finding which agrees with suggestions that TB patients who also have DM should be managed in the same setting.[11],[17] These findings are contrary to reports from Maryland, India, and Nigeria, all of which reported differences in treatment outcomes between TB and TBDM patients where TBDM patients had poorer outcomes.[18],[19],[20] However, studies from Thailand and India reported comparable treatment outcomes between both groups of patients where early screening of DM enhanced early diagnosis in TB patients which ultimately led to better glycaemic control during anti-TB treatment, resulting in favorable and comparable treatment outcomes.[21],[22] The difference observed in other studies could have been due to lack of CC as a result of traditional management in separate clinics, DM-associated pill burdens, or uncontrolled glycemic levels.[6],[23] However, the treatment success recorded in this study was just short of the WHO target of 85% treatment success rate.[2] The significant determinants of treatment success in this study were being adherent to treatment, having no ADR, and being in CC management. Having no ADR being a predictor of treatment success agrees with a study in India where having an ADR predisposes TBDM patients to greater risks of treatment failure.[19]

Consistent with reports, about half, 46.2% of TBDM patients in this study were newly diagnosed with DM.[7] Similar studies in India and Indonesia reported newly diagnosed DM of 40% and 73%, respectively, among TB patients.[19],[24] This calls for a high index of DM suspicion in presenting TB patients. High rates of undiagnosed DM predispose to infections such as TB and/or complications of the disease, contributes to adverse TB treatment outcomes, and undermines the ongoing global control efforts for TB.[10],[25] TBDM co-morbidity in this study was significantly associated with being female, of older age, higher body weights, and having a family history of DM. Almost all TBDM patients (92.3%) were older than 40 years when compared to patients with TB only (35.5%). This agrees with suggestions by the WHO and the IULTD[11] and implies that in our setting, to screen and detect over 90% of TB patients who are likely to have DM, only patients older than 40 years need to be screened.

Exposures to TB infection and the presence of TB risk factors are the bedrock of infection. The lesser contacts with active TB cases reported by TBDM patients in this study implies that the development of TB in diabetic patients could have occurred not only as a result of exposure to infectious TB cases but as a result of other factors, such as immune suppressive effects of DM and subsequently reduced immunity in diabetic patients.[17] This is consistent with reports from Ethiopia[26] but contrary in Indonesia where Alisjahbana et al., reported more symptoms in TBDM patients, but with no evidence of more severe disease. Similarly, higher blood pressures recorded among TBDM patients suggests the presence of diabetic risk factors, which if not promptly addressed at the onset could have contributed to the development of DM and the subsequent reduction in their innate adaptive immunity and infection with TB.[6]

FBG and HbA1c being indicators of glycemic control, reflects average plasma glucose over the previous 8 to 12 weeks. In this study, the mean FBG and HbA1c values for TBDM patients were expectedly higher than those of TB-only patients, and also well above recommended values[15] at TB treatment initiation. This is not ideal and indicates that DM was poorly controlled before the patients developing TB and this could have been instrumental to the patient's susceptibility to infections. Reductions in FBG and HbA1c values noted from treatment initiation to completion could have been as a result of collaborative and comprehensive care offered to TBDM patients, thus improving glycemic control, which in turn could have contributed to eliminating the expected worse treatment outcomes attributable to DM. This finding confirms reports that early screening and enhanced DM care may mitigate the impact of adverse effects of DM on TB treatment outcomes.[6],[11],[22] Higher FBG values observed in newly diagnosed TBDM patients call for targeting them with interventions to improve glycemic control and subsequently treatment outcomes. A 1% increment in HbA1c has been associated with a 10%–30% increase risk for total stroke, coronary heart disease, and all-cause deaths.[27]

Multiple drug therapy is the cornerstone of TB treatment and patients may experience a variety of significant ADRs when managed with first-line anti-TB drugs. In this study, almost half (41.7%) of all patients reported at least one ADR. A significantly higher number of TBDM patients reported 2 or more ADRs, which required more therapy modifications compared to their TB counterparts. This could have been caused by the concomitant presence of TB and DM in patients, coupled with the use of multiple drugs in managing both conditions. In addition, TBDM patients also reported higher percentages of ADRs stratified by body organs, the most frequent being systemic signs and symptoms, such as fever, general body weakness, and pain. GIT-related ADRs: Epigastric pain, nausea, vomiting, diarrhea was also rampant, probably due to synergistic side effects of their respective anti-tuberculous and antidiabetic medications. It could also have been as a result of the manifestation of more severe disease in TBDM comorbidity and/or diabetic-related side effects. Other lesser experienced ADRs were skin related: Skin rashes and pruritus, reproductive: Amenorrhea, and classic diabetes-related neuropathy. Similar high proportions of ADRs significantly associated with the presence of DM were reported in India.[19] Contrary to this were those observed in Malaysia.[28] Other studies among TB patients only reported severe side effects of anti-TB drugs as common in patients who have risk factors for ADRs.[29],[30]


The findings of this study demonstrated that the provision of CC with DOTS eliminated the expected worse TB treatment outcomes in TB patients who also have comorbid DM while ensuring improved TB treatment outcomes, which is comparable to those of TB only patients. The study showed that interventions offered by a clinical pharmacist led to reductions in glycaemic and fasting blood levels, and had a positive impact in improving the likelihood of achieving treatment success and cure rates while reducing adverse outcomes.


The authors are grateful to Dr. O. Adesola (Infectious clinic, mainland hospital, Yaba), Dr. M. Lawal (DOTS clinic, GH, Odan, Lagos), and Dr. O. Akinlade (Endocrinology clinic, GH, Odan, Lagos) for their encouragement and support of this research in their institutions. We are grateful to the staff of the three clinics for their cooperation. We also thank all patients for participating in this study.

Ethical clearance

The study was approved by the institutional Ethics Committee of Lagos University Teaching Hospital (Approval No: ADM/DCST/HREC/APP/665).

Financial support and sponsorship


Conflicts of interest

There are no conflicts of interest.


1Dooley KE, Chaisson RE. Tuberculosis and diabetes mellitus: Convergence of two epidemics. Lancet Infect Dis 2009;9:737-46.
2Global tuberculosis report. World Health Organization, Geneva; 2020. Licence: CC BY-NC-SA 3.0 IGO. 2020.
3Ogurtsova K, da Rocha Fernandes JD, Huang Y, Linnenkamp U, Guariguata L, Cho NH, et al. IDF diabetes atlas: Global estimates for the prevalence of diabetes for 2015 and 2040. Diabetes Res Clin Pract 2017;128:40-50.
4Noubiap JJ, Nansseu JR, Nyaga UF, Nkeck JR, Endomba FT, Kaze AD, et al. Global prevalence of diabetes in active tuberculosis: A systematic review and metaanalysis of data from 2.3 million patients with tuberculosis. Lancet Glob Health 2019;7:e448-60.
5Ahmed M, Omer I, Osman SM, Ahmed-Abakur EH. Association between pulmonary tuberculosis and type 2 diabetes in Sudanese patients. Int J Mycobacteriol 2017;6:97-101.
6Niazi AK, Kalra S. Diabetes and tuberculosis: A review of the role of optimal glycemic control. J Diabetes Metab Disord 2012;11:28.
7Fasanmade OA, Dagogo-Jack S. Diabetes Care in Nigeria. Ann Glob Health 2015;81:821-9.
8Ogbera AO, Kapur A, Chinenye S, Fasanmade O, Uloko A, Odeyemi K. Undiagnosed diabetes mellitus in tuberculosis: A Lagos report. Indian J Endocrinol Metab 2014;18:475-9.
9Ekeke N, Ukwaja KN, Chukwu JN, Nwafor CC, Meka AO, Egbagbe EE, et al. Screening for diabetes mellitus among tuberculosis patients in Southern Nigeria: A multi-centre implementation study under programme settings. Sci Rep 2017;7:44205.
10Baker MA, Harries AD, Jeon CY, Hart JE, Kapur A, Lönnroth K, et al. The impact of diabetes on tuberculosis treatment outcomes: A systematic review. BMC Med 2011;9:81.
11World Health Organization and International Union Against Tuberculosis and Lung Disease. Collaborative framework for care and control of tuberculosis and diabetes. Geneva: World Health Organization; 2011 (WHO/HTM/TB/2011.15) [Last accessed on 2021 Jul].
12Lagos State Government. Population of Lagos State; 2019. Available from: [Last accessed on 2019 Sep 16].
13Sullivan KM, Soe MM. Documentation for Sample Size for an Unmatched Case-Control Study; 2007. Available from: www.openepi. com/SampleSize/SSCC.h. [Last accessed on 2015 Jul 15].
14Federal Ministry of Health. Department of Public Health. National Tuberculosis and Leprosy Control Programme (NTBLCP). Worker's Manual - Revised 5th Edition, 2010. p. 11-63.
15American Diabetes Association. Classification and diagnosis of diabetes: Standards of medical care in diabetes-2018. Diabetes Care 2018;41:S13-27.
16World Health Organization. Definitions and Reporting Framework for Tuberculosis: 2013 Revision (Updated December 2014). Geneva: World Health Organization; 2013.
17Harries AD, Kumar AM, Satyanarayana S, Lin Y, Zachariah R, Lönnroth K, et al. Diabetes mellitus and tuberculosis: Programmatic management issues. Int J Tuberc Lung Dis 2015;19:879-86.
18Dooley KE, Tang T, Golub JE, Dorman SE, Cronin W. Impact of diabetes mellitus on treatment outcomes of patients with active tuberculosis. Am J Trop Med Hyg 2009;80:634-9.
19Siddiqui AN, Khayyam KU, Sharma M. Effect of diabetes mellitus on tuberculosis treatment outcome and adverse reactions in patients receiving directly observed treatment strategy in India: A prospective study. Biomed Res Int 2016:7273935.
20Ayeni F, Aina B, Oyetunde O, Adejumo O. Associated factors and treatment outcomes of tuberculosis patients with diabetes mellitus in a secondary health facility in Lagos, Nigeria. West Afr J Pharm 2016;27:1-9.
21Duangrithi D, Thanachartwet V, Desakorn V, Jitruckthai P, Phojanamongkolkij K, Rienthong S, et al. Impact of diabetes mellitus on clinical parameters and treatment outcomes of newly diagnosed pulmonary tuberculosis patients in Thailand. Int J Clin Pract 2013;67:1199-209.
22Desai A, Gupta N, Korishetty L, Saravu K. Treatment outcomes of patients with tuberculosis and diabetes: A prospective cohort study from India. Int J Mycobacteriol 2021;10:111-5.
23Yoon YS, Jung JW, Jeon EJ, Seo H, Ryu YJ, Yim JJ, et al. The effect of diabetes control status on treatment response in pulmonary tuberculosis: A prospective study. Thorax 2017;72:263-70.
24Alisjahbana B, Sahiratmadja E, Nelwan EJ, Purwa AM, Ahmad Y, Ottenhoff TH, et al. The effect of type 2 diabetes mellitus on the presentation and treatment response of pulmonary tuberculosis. Clin Infect Dis 2007;45:428-35.
25World Health Organization. End TB Strategy: Global Strategy and Targets for Tuberculosis Prevention, Care, and Control After 2015. Geneva: World Health Organization; 2014 Available from: Strategy.pdf?ua=1. [Last accessed on 2109 Mar 15].
26Amare H, Gelaw A, Anagaw B, Gelaw B. Smear positive pulmonary tuberculosis among diabetic patients at the Dessie referral hospital, Northeast Ethiopia. Infect Dis Poverty 2013;2:6.
27Control Group, Turnbull FM, Abraira C, Anderson RJ, Byington RP, Chalmers JP, et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia 2009;52:2288-98.
28Aweis DM, Suleiman SA. Role of diabetes mellitus on adverse drug reaction to anti-tuberculosis drugs. JAMPS 2020;22:34-9.
29Farazi A, Sofian M, Jabbariasl M, Keshavarz S. Adverse reactions to antituberculosis drugs in Iranian tuberculosis patients. Tuberc Res Treat 2014;2014:1-6.
30Amalba A, Bugri AA. Assessing the prevalence and effect of adverse drug reactions among patients receiving first line anti-tubercular medicines in the Tamale Teaching Hospital, Ghana. Pan Afr Med J 2021;38:191.